No Stomach For Cancer

DID YOU KNOW

There are 6 common stomach cancer biomarkers?

Currently, there are two known categories of stomach cancer biomarkers: genetic and MSI-high (microsatellite instability-high).

HER2: HER2 positive tumors have above normal HER2 protein, which causes cancer cells to grow.

MSI-high and dMMR: When cells are unable to correct DNA errors, they can replicate uncontrollably, and cause cancer.

PD-L1: Cells with too much of the PD-L1 protein allow gastric cancer cells to evade the immune system.

TMB: Tumors with more than one mutation have a high tumor mutational burden (TMB).

EBV: Epstein-Barr virus may play a role in transforming normal stomach cells into cancerous ones.

Tumor-agnostic biomarkers: Some biomarkers such as NTRK, BRAF mutations and RET fusions are not specific to stomach cancer.

There are also emerging biomarkers: As new biomarkers are identified and researched, more individualized treatment will become available.

If you have potential or known risk factors for you should consider registering for this event.

Lynch Syndrome Center Webinar - Hereditary Cancer Risk Calculator: What Is It and How Do I Use It? What is cancer genetic testing? Would this testing be recommended for me? The UCSF Lynch Syndrome Center is offering a series of educational workshops to provide more information on recommendations for cancer genetic testing using UCSF’s new Hereditary Cancer Risk Calculator tool. We aim to provid...

More than 10,000 rare diseases, affecting fewer than 200,000 people, impact the lives of over 30 million Americans. People with rare diseases face unique challenges, such as receiving a timely and accurate diagnosis and obtaining adequate health coverage, including affordable care and treatment. Join us to learn how states can address out-of-pocket costs for patients with rare diseases.

Decreasing Drug Costs for Patients with Rare Disease More than 10,000 rare diseases, defined as those affecting fewer than 200,000 people, impact the lives of over 30 million Americans. People living with rare diseases face unique challenges such as receiving a timely and accurate diagnosis and obtaining adequate health coverage, including affordable....

The Seahorse Digest Newsletter - July 2024

A SEMI-REGULAR NEWSLETTER WITH BITE-SIZED PIECES OF INFORMATION ABOUT CDH1 RESEARCH AT The NIH Clinical Center

Too many patients have died of stomach cancer who could have benefited from targeted treatments if they had received timely biomarker testing.

The high mortality rate associated with stomach cancer demands we raise awareness of and advocate for biomarker testing, which we know can lead to targeted treatments that improve patient outcomes and increase survival rates.

We started the Test Your Biomarkers campaign to raise awareness about the importance of biomarker testing in treating stomach cancer for patients and their loved ones, because the best treatment for your stomach cancer can be individualized.

Registration is Now Open for the Fall 2024 Spotlight on Stomach Cancer at Penn Medicine - Abramson Cancer Center

https://www.med.upenn.edu/stomach2024/

It’s an honor to be part of this campaign

Thank you to our founding supporter Stomach for Cancer for your dedication and commitment to raising awareness about the importance of biomarker testing in treating stomach cancer.

No Stomach For Cancer is a non-profit patient advocacy organization that advances awareness and education about stomach cancer.

The organization supports research efforts for screening, early detection, treatment, and prevention, and unites the caring power of people worldwide affected by stomach cancer.

Learn more on their site https://nostomachforcancer.org/

Were you or someone you know just diagnosed with stomach cancer?

You are not alone and we are here to help.

Our website is full of resources for patients and caregivers to help along this journey. First: What questions should you ask your health care team about getting tested for biomarkers?

Download a script on our website to take with you to your next appointment.

https://testyourbiomarkers.org/downloadable-biomarker-script/

Awareness is important in any language and culture.

https://www.publico.pt/2024/06/19/ciencia/video/farewell-my-stomach-story-of-portuguese-family-20240618-173158

“Farewell, my stomach”: a Portuguese family story A Portuguese family shares their sorrows and hopes, deeply entangled with the double face of a gene.

Last week, we joined healthcare and industry professionals, other PAOs, and patients for the first-ever Patient Advocacy Organization (PAO) Action Week. We’re so grateful to everyone who supported this initiative that helped raise awareness of the support PAOs like No Stomach For Cancer provide for the stomach cancer community.

Thank you, Astellas Pharma US

A new and informative research paper from Dr. Jeremy Davis’s team at the National Cancer Institute

https://jamanetwork.com/journals/jama/fullarticle/2820241

Germline CDH1 Variants and Lifetime Cancer Risk This cross-sectional study describes the risk estimates for gastric and breast cancer for individuals with CDH1 variants.

Currently, there are two known categories of stomach cancer biomarkers: genetic and MSI-high (microsatellite instability-high). Biomarkers are often referred to by a
three- or four-letter abbreviation.

Microsatellite Instability High (MSI-high) are short, repeated strings of DNA. Cancer cells that are MSI-high contain a high number of mutations, which can make them extra sensitive to drugs called immunotherapy checkpoint inhibitors. Several known MSI-high biomarkers can be targeted in treatment.

We're proud to support the inaugural Patient Advocacy Organization (PAO) Action Week to recognize the important role organizations like ours have in helping patients and their loved ones on their stomach cancer journey.

Throughout , we highlight the meaningful support, advocacy, and community PAOs provide for patients nationwide.

Join us in empowering patients and caregivers and bringing awareness to PAOs:

Learn more about the campaign here: bit.ly/4bJXdU6

Thank you Gretchen Mauro Borzi for continuing to advocate for patients and families and for your time serving on our board of directors.

https://www.massgeneral.org/cancer-center/news/genetic-testing-cdh1-mutation-patient-story

Patient Stories: CDH1 Gene Mutation—Gretchen | Massachusetts General Hospital The discovery of a CDH1 gene mutation in the family led Gretchen Borzi on a journey of genetic testing and preventative surgery with a multidisciplinary team. Learn more.

We are so proud and excited to have the ability to provide vital and necessary funding to one of the most talented and caring stomach cancer doctors at the National Institutes of Health (NIH). Dr. Jeremy Davis is considered to be a leading expert in the research and care of stomach cancer patients with sporadic and hereditary diseases.

This new grant will help support ongoing CDH1 family research efforts at the National Cancer Institute and could not have been possible without your financial support.

The check was presented to Dr. Davis at the National Institutes of Health (NIH) Inaugural Think Tank on Gastric Cancer Prevention.

Currently, there are two known categories of stomach cancer biomarkers: genetic and MSI-high (microsatellite instability-high). Biomarkers are often referred to by a
three- or four-letter abbreviation.

Human Epidermal Growth Factor Receptor 2 (HER2) is a genetic biomarker.

The HER2 gene makes HER2 proteins, which can make cancer grow. When stomach cancer cells contain a higher-than-normal amount of the HER2 protein, they can grow more quickly and spread to other parts of the body. These tumors can be treated with targeted antibody drugs.

Third-Party Paid Market Research Study - Experiences with Stomach Cancer.

• Participation consists of a one-time, anonymous 90-minute online discussion with a researcher sharing experiences about your patient journey.
• Dates: June 6th-7th (various times available)
• Incentive: $250 paid within 1-2 weeks

All interested patients will take the appropriate pre-screening questionnaire to gauge eligibility. No treatments will be offered at this time, and they are not selling anything. The information gathered will remain confidential and used for research purposes only.

PATIENTS can apply here https://surveys.opinionslink.com/r/4PQnSM

Know the Symptoms. Know the Risks.

Push Hard for Answers. Advocate for Yourself.

I Was Diagnosed With Stomach Cancer at 32. Here Are the First Symptoms I Noticed I kept calling my doctor’s office for updates, but the receptionist told me he was busy.

Members of the U.S. Military and U.S. Veterans have access to specific benefits, programs, and resources that may be useful after a cancer diagnosis. This webinar will explore the benefits available to Veterans and how they may work with other benefits Veterans already have.

Webinar Registration (2024) - Benefits for Veterans with Cancer During this live and interactive webinar, social workers and nurses in attendance obtain a better understanding of the benefits available to Veterans and how they may work with other benefits Veterans already have.

Know the Symptoms. Know the Risks. Push hard for answers.

Mum life turned upside-down after holiday tummy bug turns out to be cancer Donna Taylor was diagnosed with inoperable stomach cancer after suffering from an upset tummy while on holiday in Turkiye and Cornwall.

DID YOU KNOW

There are 6 common stomach cancer biomarkers?

Currently, there are two known categories of stomach cancer biomarkers: genetic and MSI-high (microsatellite instability-high).

HER2: HER2 positive tumors have above normal HER2 protein, which causes cancer cells to grow.

MSI-high and dMMR: When cells are unable to correct DNA errors, they can replicate uncontrollably, and cause cancer.

PD-L1: Cells with too much of the PD-L1 protein allow gastric cancer cells to evade the immune system.

TMB: Tumors with more than one mutation have a high tumor mutational burden (TMB).

EBV: Epstein-Barr virus may play a role in transforming normal stomach cells into cancerous ones.

Tumor-agnostic biomarkers: Some biomarkers such as NTRK, BRAF mutations and RET fusions are not specific to stomach cancer.

There are also emerging biomarkers: As new biomarkers are identified and researched, more individualized treatment will become available.

Please feel free to join the live stream at the Think Tank on Advancing Gastric Cancer Prevention

Join our Cloud HD Video Meeting Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference room solution used around the world in board, confer...

This event will feature the latest updates to the clinical guidelines for hereditary diffuse gastric cancer.

Penn Medicine Penn Medicine - Abramson Cancer Center

‘How I knew I had stomach cancer’: Six survivors share their symptoms What are the symptoms of stomach cancer, and when should you see a doctor about them? Here, surgical oncologist and gastrointestinal cancer specialist Paul Mansfield, M.D., weighs in, and six survivors share how they knew they had stomach cancer.

Advocating today for Stomach Cancer patients and their families with Hope For Stomach Cancer and those who are looking for hope from our lawmakers.

Survival Outcomes and Patterns of Care for Stage II or III Resected Gastric Cancer by Race and Ethnicity

"Among patients with stage II or III gastric adenocarcinoma undergoing a curative surgical procedure, there were variations in overall survival associated with race and ethnicity."

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813183

Astellas Pharma is working to address Access to Health (ATH) issues in various countries.

In Brazil, gastric cancer is one of the leading causes of death, and early treatment intervention through improved medical literacy is an issue in accessing medical care.

https://www.astellas.com/en/sustainability/astellas-healthcare-e-city



Astellas Pharma US

Astellas Healthcare E-city | Astellas Pharma Inc. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug inclu...